Literature DB >> 2974700

Characterization of receptor tyrosine-specific protein kinases by the use of inhibitors. Staurosporine is a 100-times more potent inhibitor of insulin receptor than IGF-I receptor.

Y Fujita-Yamaguchi1, S Kathuria.   

Abstract

The receptors for insulin and insulin-like growth factor (IGF)-I carry intrinsic tyrosine-specific protein kinases (TPK) in their cytoplasmic domains that show 84% homology. Our previous studies using tyrosine-containing synthetic polymers (Arch. Biochem. Biophys. 260, 416, 1988) revealed subtle differences between the two receptor TPKs. In the present study, low molecular weight kinase inhibitors were used to compare the two receptor TPKs purified from human placenta. Staurosporine was the most potent inhibitor of both receptor TPKs among the three inhibitors tested. It was 100 times more inhibitory to insulin receptor TPK (ED50 = 61nM) than IGF-I receptor TPK (ED50 = 6.2 microM). Apigenin and kaempferol showed approximately the same inhibitory potency toward both TPKs with a range of 10 approximately 1000 microM. Staurosporine is thus an excellent tool to biochemically characterize the two receptor TPKs as well as to selectively inhibit insulin-activated TPK in intact cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2974700     DOI: 10.1016/s0006-291x(88)80967-7

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

1.  Induction of neutrophil homotypic adhesion via sialophorin (CD43), a surface sialoglycoprotein restricted to haemopoietic cells.

Authors:  A R Rosenkranz; O Majdic; J Stöckl; W Pickl; H Stockinger; W Knapp
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

2.  Inhibition of neuronal cyclin-dependent kinase-5 by staurosporine and purine analogs is independent of activation by Munc-18.

Authors:  K T Shetty; N Amin; P Grant; R W Albers; H C Pant
Journal:  Neurochem Res       Date:  1996-05       Impact factor: 3.996

3.  Effect of inhibitors of protein kinase C on enhanced superoxide production of human leucocytes by ofloxacin and fleroxacin.

Authors:  T Matsumoto; K Takahashi; T Nagafuji; S Kubo; J Kumazawa
Journal:  Drugs       Date:  1995       Impact factor: 9.546

4.  Possible roles of protein kinases in neutrophil chemotactic factor production by leucocytes in allergic inflammation in rats.

Authors:  J Tanabe; M Watanabe; S Kondoh; S Mue; K Ohuchi
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

5.  Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411.

Authors:  P Furet; G Caravatti; N Lydon; J P Priestle; J M Sowadski; U Trinks; P Traxler
Journal:  J Comput Aided Mol Des       Date:  1995-12       Impact factor: 3.686

6.  Effect of basic polycations and proteins on purified insulin receptor. Insulin-independent activation of the receptor tyrosine-specific protein kinase by poly(L-lysine).

Authors:  Y Fujita-Yamaguchi; D B Sacks; J M McDonald; D Sahal; S Kathuria
Journal:  Biochem J       Date:  1989-11-01       Impact factor: 3.857

7.  Staurosporine induces rapid homotypic intercellular adhesion of U937 cells via multiple kinase activation.

Authors:  Jae Youl Cho; David R Katz; Benjamin M Chain
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

8.  Multiple kinase arrest points in the G1 phase of nontransformed mammalian cells are absent in transformed cells.

Authors:  D M Gadbois; H A Crissman; R A Tobey; E M Bradbury
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

9.  Okadaic acid, an inhibitor of protein phosphatases 1 and 2A, inhibits induction of acute-phase proteins by interleukin-6 alone or in combination with interleukin-1 in human hepatoma cell lines.

Authors:  M K Ganapathi
Journal:  Biochem J       Date:  1992-06-15       Impact factor: 3.857

10.  Sensitization of C6 glioma cells to radiation by staurosporine, a potent protein kinase C inhibitor.

Authors:  W Zhang; H Yamada; N Sakai; Y Nozawa
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.